☰
×
Top 20
Insights
Insight+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
App
Advertisement
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
UCB
UCB Reports Data of Bimekizumab in P-III (BE MOBILE 1) and (BE MOBILE 2) Studies for the Treatment of Axial Spondyloarthritis (axS...
May 24, 2022
UCB Presents Efficacy and Safety Results of Zilucoplan and Rozanolixizumab in P-III (RAISE) & (MycarinG) Study for Generalized Mya...
May 11, 2022
UCB Publishes Results of Fintepla (fenfluramine) in the P-III Trial for the Treatment of Seizures Associated with Lennox-Gastaut S...
May 3, 2022
UCB’s Fintepla (fenfluramine) Receives the US FDA’s Approval for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome
March 29, 2022
UCB’s Bimzelx (bimekizumab) Receives Health Canada’s Approval for the Treatment of Plaque Psoriasis
February 18, 2022
UCB Signs a Definitive Agreement to Acquire Zogenix for ~$1.9B
January 19, 2022
Load more...
No more records!